

EU Funding for Health



Dr. Martha Cahill., MBA

martha.cahill@enterprise-ireland.com


NCP for Health

Tel: 00-353-1-808-2748

- *Background*
- *The Rules of Participation*
- *Project Structures*
- *Examples*
- *The Health Theme*
- *The Technology Platforms*
- *European Research Council*
- *The Evaluation Process*
- *Enterprise Ireland Support*

- In March 2000, EU heads of state and government agreed on an ambitious goal:

*The most competitive and dynamic and knowledge-based economy in the world,
Capable of sustainable economic growth,
With more and better jobs and
Greater social cohesion.*
by 2010.



- Kok Report - "Facing the Challenge"

http://europa.eu.int/growthandjobs/pdf/kok_report_en.pdf

FP7 will run for a seven period 2007 to 2013.




- It will be fully operational as of 1 January 2007.

No funding in 2006

<i>FP7 Budget</i>	Proposed Budget	Confirmed Budget
Total EC Budget	€73 billion	€54.2 billion
Health	€8 billion	~ €6 billion

FP7 Budget- €54.2 Bn



Cooperation Programme


7th Framework -9 themes proposed

1. **Health**
2. Food, agriculture and biotechnology
3. Information and communication technologies
4. Nanosciences, Nanotechnologies, Materials and new Production Technologies
5. Energy
6. Environment and Climate Change
7. Transport and Aeronautics
8. Socio-economic sciences and the humanities
9. Space and Security Research

Thematic Breakdown

Thematic Area	Budget (€m)	%
<i>Health</i>	<i>6,050</i>	<i>19</i>
Food, Agriculture and Biotechnology	1,935	6
<i>Information and Communication Technologies</i>	<i>9,110</i>	<i>28</i>
<i>Nanosciences, Nanotechnologies, Materials and new Production Technologies</i>	<i>3,500</i>	<i>11</i>
Energy	2,300	7
Environment (including Climate Change)	1,900	6
<i>Transport (including Aeronautics)</i>	<i>4,180</i>	<i>13</i>
Socio-economic Sciences and the Humanities	610	2
Space & Security	2,780	9
Total Cooperation Budget	32,365	

Thematic Breakdown



The Rules of Participation


The Rules of Participation determine

who can participate in FP7,

the criteria for participation &

what the EU contribution will be for successful applicants.

FP7 Co-decision Procedure









Who can participate?

Various types of entities include the Following:

- Academic researchers – Universities, Institutes of Technology
- Small to Medium Enterprises (SME's)
- Multinational Companies
- Medical Doctors, Research Nurses & public health organisations.
- Clinical Research Organisations
- Consultants
- Software companies
- Technology Companies (eg. device or electronics companies)
- Others...

Rule of Participation – Location of Participants

	Coordinator
	University
	Hospital
	SME's
	MNC



The Various Countries

25 Member States

Associated Countries

e.g. Israel

Third Countries

US, Canada, Australia

Rule of Participation for FP7 – The Financials

The effect of the removal of the additional cost model

Activities	FP6 Calculations			FP7 Calculations	
	Public Bodies	SMEs (FCF)	Full Cost	Public Bodies/SMEs	Full Cost
	% (AC)	%	%	%	%
RTD/Innovation	100	50	50	75	50
Demonstration	100	35	35	50	50
Training	100	100	100	100	100
Management	100	100	100	100	100

- Financial details have not been resolved yet.
 - Overhead rates - Flat-rate
 - Simplified methods for calculating overheads.
 - Ireland is requesting a flat-rate of 50%

- Timeline ??

Project Structures

INSTRUMENTS

FP6	FP7
Specific Targeted Research Project (STREP)	Collaborative Projects
Integrated Projects (IP)	
Specific Support Actions (SSA)	Coordinated and Support Actions
Co-ordinated Action (CA)	
Network of Excellence (NOE)	Network of Excellence (NOE)

Specific Targeted Research Project (STREP)

Small research project

Funding up to **€3 million**

Average duration **2 - 3 years**

Integrated Projects (IP)

Large Research projects

Funding up to **€25 million**

Average duration **3 – 5 years**

Requirements for EU Funding

- International Collaboration
 - legal minimum of 3 different Countries
 - But more partners required in reality
-
- STREP's 6-15 Partners
 - Integrated Projects 10-20 Partners

*FP7 – STREP's and IP become collaborative projects
Awaiting clarification on these!!*

Examples

- LSH-2005-2.2.0-2: Modulation of apoptosis in cancer prevention and therapy. The project will aim at unravelling and targeting critical apoptotic signalling pathways relevant to the formation of solid tumours. *Multidisciplinary consortia* should focus on the development and (pre)clinical validation of novel anti-cancer drugs with a wide therapeutic index that address apoptotic evasion and stimulate programmed cell death in solid tumours. Studies that tackle P53, conventional cytotoxic chemotherapeutic agents or cell-based immunotherapy will be excluded from this topic.

Network of Excellence.

- ◆ Strengthen scientific and technology Excellence.
 - ◆ Aimed at tackling the fragmentation of existing research.
 - ◆ Proposed for the Integration of activities, joint research programmes, and joint training programmes.
-
- Participants – as many as possible. Optimal size 6- 12 participants.
 - Funding between: € 4 to 15 million.
 - Average = € 7 Million
 - Duration: 4-5 years.

Combating, cardiovascular disease, diabetes and rare diseases

LSH-2005-2.1.1-2:

- **Hypertension and cardiovascular disease.** The project should lead to the integration of research teams working on genetics, functional genomics and molecular mechanisms of hypertension and hypertension-related cardiac and vascular damage.

Specific Support Actions (SSA)

- To complement other FP 6 grants, to aid in preparations for future EU RTD policy initiatives,
- 2 types:
 1. *Support activities*: conference & seminar organization, performance of studies, high level scientific awards & competitions.
 2. *Project management activities*
- Partners: Single or a group of partners (1-15 participants).
- Funding between: € 0.03 to 1 million.
- Average €0.5 million
- Duration: Typically 'one-off' event 9 to 30 months

Other actions across thematic priority 1 LSH-2005-3-1:

- **Promoting Collaboration between SMEs and Academia:** Innovative activities aiming at stimulating and strengthening collaboration between SMEs and researchers in specific areas supported by the Theme will also be considered for support.

Coordinated Action (CA)

- Purpose – Coordinated Networking
- Intended to improve and effect the coordination of research.

Meetings,

Workshops,

Study analysis,

Exchanges & dissemination of good Practices,

Seminars,

Working groups,

Exchanges of personnel,

- Partners: Optimum 13-26 participants
- Funding between: € 0.5 to 1.2 million.
- Average €1 million
- Duration: 1.5 -3 years

Example of a Coordinated Action (CA)

Fundamental knowledge and basic tools for functional genomics in all organisms LSH-2005-1.1.0-1

- Proposals for Co-ordination Actions (CA) in functional genomics research (proteomics, gene expression, structural genomics, comparative genomics, population genetics, bioinformatics, multidisciplinary functional genomics approaches to basic biological processes) will also be considered.

The Health Theme

Nature of the Research projects

7th Framework -9 themes proposed.

1. **Health**
2. Food, agriculture and biotechnology
3. Information and communication technologies
4. Nanosciences, Nanotechnologies, Materials and new Production Technologies
5. Energy
6. Environment and Climate Change
7. Transport and Aeronautics
8. Socio-economic sciences and the humanities
9. Space and Security Research

Activities are in 3 main areas

1. *Biotechnology, generic tools and technologies for human health*
2. *Translating research for human health*
3. *Optimising the delivery of healthcare to European citizens*

1. Biotechnology, generic Tools and technologies for human health.

- ◆ High throughput research
 - ◎ New technologies for Genotyping, phenotyping & other 'omics'
- ◆ Detection, diagnosis and monitoring
 - ◎ Imaging, Nanotechnology, Devices and IT
- ◆ Predicting, suitability, safety and efficacy of therapies
 - ◎ Toxicology testing methods, new methods for safety assessment of new therapeutic approaches
- ◆ Innovative therapeutic approaches and intervention
 - ◎ Gene and cell therapy, regenerative medicine, targeted drug delivery and advance implants

2. Translating research for human health

- ◆ Integrating Biology data and processes
 - ◎ large-scale data gathering, systems biology.
- ◆ Research on the brain and related diseases, human development and aging.
- ◆ Translational research in infectious Diseases.
 - ◎ HIV, Aids, Malaria, TB, Emerging Diseases.
- ◆ Translational research in major Diseases:
 - ◎ Cancer, cardiovascular disease, diabetes/obesity; rare disease; and other chronic disease (e.g. osteoarthritis)

3. Optimising the delivery of health care to European Citizens

- ◆ Enhanced health promotion and disease prevention
 - ⊙ Public health measures – life styles, interventions, special focus on mental health.
- ◆ Translating clinical research into clinical practice
 - ⊙ patient safety, better use of medicines, benchmarking, pharmacovigilance.
- ◆ Quality, solidarity and sustainability of health systems
 - ⊙ organisational and financial aspects, health systems

- Clinical Trials Phase I and II
- Poverty related diseases - Clinical trials - Phase III
 - ◎ HIV, Aids, Malaria, TB, Emerging Diseases.

The Technology Platforms

Technology Platform for Innovative Medicines




Aim

*To remove major bottlenecks in the drug development,
acting where research is the key.*

Separate proposed budget was originally
€440 Million per year

Now possibly will start with €100million
(50:50 contribution by EU Commission and Industry)

R&D bottlenecks identified by stakeholders



Source: EFPIA, 2005

Addressing R&D bottlenecks in 4 main areas

1. Prediction of Safety,
2. Early indication of Efficacy,
3. Knowledge Management and
4. Education & Training.

Industry led initiative

Co-founders are the European Commission & European Federation of Pharmaceutical Industries and Associations (EFPIA)

Expected outcomes

- Improved drug development process
- Increased attractiveness to do (bio)-pharmaceutical R&D in Europe
- Reduced risk of failure

European Technology Platform for NanoMedicine

*Research that Involves the application of
Nanotechnology for Health*

3 areas have been identified

1. Nanotechnology-based Diagnostics including Imaging
2. Targeted Drug Delivery and Release
3. Regenerative Medicine



European Research Council

European Research Council (ERC)

- Pan-European Funding organisation designed to support the best science and scholarships. http://europa.eu.int/erc/index_en.cfm

(Similar Structure and function as Science Foundation Ireland)

ERC Scientific Council

- ❖ 22 founding members of the Scientific Council from across Europe
- ❖ Policy-setting supervisory body of the ERC.
- ❖ Promote innovative research
- ❖ Direct the scientific strategy
- ❖ Oversee the operational management of the ERC
- ❖ Selection of proposals
- ❖ Funding decisions
- ❖ Independence and transparency of the ERC's operations.

- Starting Independent Researcher Grants

- First Priority or Funding Stream*

- Support to researchers who are at the stage of establishing their first research team or pursuing their independent research.

- Advanced Investigator Grants

- Second Funding Stream*


- Advanced Investigator Grant at all career stages.

The Evaluation Process

Not outlined for FP7 yet!

Length of the process

- ◆ Six months between the opening and closing of a call
- ◆ 4-5 months for results



Review/Evaluation process

- ◆ External review by at least 3 independent evaluators.
(5 for an integrated Project)



Evaluation Reports

- ◆ Both successful and unsuccessful applicants are given an evaluation report.

Evaluation of a Proposal

1. Relevance	Threshold	3/5
2. Potential impact	Threshold	3/5
3. S&T excellence	Threshold	4/5
4. Quality of the consortium	Threshold	3/5
5. Quality of the management	Threshold	3/5
6. Mobilisation of the resources	Threshold	3/5

“Successful EU projects deal with more than scientific excellence”.

- ◆ Intellectual property issues
- ◆ Details of commercialisation/clinical trials
- ◆ Complementary partners & ethical issues
- ◆ Partners ability to manage large projects

Ineligible Proposals

- The main problem is proposals are late arriving

90% of proposals are submitted in the last 2 days.

77% of proposals are submitted in the last day.

33% arrive in the last hour.

- Eligibility Committee

- ◆ 5 members - examines the proposals
- ◆ If the Commission is at fault for the submission they are considered eligible.

- Another issue is proposals do not have the minimum number of countries (3).

Look at work programmes for

- Health,
- Nanosciences and Nanotechnology
- and ICT???
- Environment & health???

Technology Platforms

- Nanomedicine
- Innovative Medicine Initiative
- Photonics : Photonics for the 21st Century
- Sustainable Chemistry ???

ERC & Marie Curie Programmes

Enterprise Ireland Support

<http://www.fp7-ireland.com>

- Currently the Support Grants are been review for FP7

This is Financial Support for applicants applying for FP7 Funding.

Contact: Brian Sheridan, Enterprise Ireland :

Tel: + 353 1 808 2428.

Email: brian.sheridan@enterprise-ireland.com

- Travel support available for FP6 has been extended

Contact: Rita Ward Enterprise Ireland

Tel: +353-1-8082767

Email: Rita.Ward@enterprise-Ireland.Com

The Advantages of a 7 year Program

- ◆ The Process, rules and procedures will be the same for the next 7 years.
- ◆ Reapply with the same or different partners.

Timeline

- ◆ Possible have a first draft of a work programme in Sept '06.
- ◆ Open calls in January 2007

BIOTECHNOLOGY IRELAND

Connecting Irish Biotechnology to the World



Home | About Us | Join | News | Events | Directory | Jobs and CVs | Links | Members | TechMate | **EU Funding** | Search


Directory

Irish Contacts

Non-Irish Contacts

Search contacts

EU Funding for Health



Profile

Events

News

[The 7th Framework Programme](#)

FP7 will run for seven years and covers the period 2007-2013. The details of the specific work programmes have not been finalised by the Commission at this time however, they aim to have the programme fully operational from 1 January 2007. Nine themes are proposed as the main priorities for [+](#)

[Technology Platforms](#)

Planning for the 7th Framework focuses on developing research through the work of Technology platforms and Joint Technology Initiatives. The Technology Platforms are detailed on CORDIS at <http://www.cordis.lu/technology-platforms>

'Technology Platforms is a mechanism to bring together all [+](#)

[More useful Documents and Reports in Healthcare and Biotechnology](#)

CORDIS: Science and Technology Foresight

The CORDIS science and Technology Foresight website details key technologies for Europe in Healthcare and Biotechnology. In 2005 the European Commission (DG Research, the 'Science and technology foresight unit') has supported an Expert Group that was [+](#)

[The Scientific Council of the European Research Council](#)

The ERC will have a unique position as a pan-European Funding organisation designed to support the best science and scholarships. The ERC Scientific Council will be the policy-setting supervisory body of the European Research Council. They will act on behalf of the scientific community in Europe [+](#)

Dr. Martha Cahill., MBA

FP7 National Contact Point for Health,
National Support Unit for FP7
Enterprise Ireland,
Tel: 01-808-2748

martha.cahill@enterprise-ireland.com

Websites & Communications

Updates: www.biotechnologyireland.com/fp7

National Support Unit : www.fp7-ireland.com